Etude
Demystifying R&D Performance in Chemicals
Demystifying R&D Performance in Chemicals
A robust assessment of R&D can help companies understand how their performance compares to others and focus investment where it matters most.
Etude
A robust assessment of R&D can help companies understand how their performance compares to others and focus investment where it matters most.
One great idea used to be enough to set a chemical company on the road to success. Leadership teams could make big bets on breakthrough ideas, and when blockbusters such as nylon, Kevlar and Gore-Tex reached the market, they often made companies—as well as the executives who championed these new ideas.
Now, the nature of innovation has changed, and there are fewer breakthrough chemicals and compounds. Innovation is still important, but increasingly, it's applied to enhancing functionality, customizing existing products or adapting products to new market opportunities.
This shift has major implications in the ways that chemical companies should manage their R&D functions. Most have recognized this shift, but Bain research finds that while two-thirds of executives say innovation is a top priority, less than 25% believe their companies are successful innovators. Many have not integrated recent innovation techniques occurring in other industries, such as Agile methodologies and digital technologies. Development cycles take too long, teams have difficulty prioritizing projects, and many senior executives see R&D as something of a black box and don't understand why returns from innovation are not higher.
Whit Keuer, a partner with Bain’s Chemicals practice, discusses three key areas that executives have to get right in order to effectively manage innovation.
Our work on innovation performance with hundreds of companies in chemicals and other industries offers insights into achieving top-quartile performance in chemicals based on the best practices of the most innovative companies from technology, healthcare, financial services and other industries. From this broad experience, three imperatives stand out for chemical companies.
With growth slowing in developed markets and demand slackening in some key developing ones, chemical executives are challenged to meet growth targets. What's more, studies of new product launches find that half fail to meet expectations. Innovation done right can help close the growth gap, but, too often, executives decide to either throw money at the problem or hope that the stage-gate process will deliver "good enough" products.
But innovation is too important to leave to chance. To demystify and improve it, executives need a better understanding of the elements of success and where they stand in relation to them.
An innovation diagnostic should reveal how R&D resources are allocated by business unit, end market and horizon (incremental, radical, breakthrough). It should also give some idea of whether the innovation pipeline is sufficient to meet growth goals. Finally, a good diagnostic needs to shed light on decision effectiveness. How are innovation decisions made, by whom, and what's the result?
As R&D is highly cross functional, it's important to assess the effectiveness of interfaces with strategy, marketing, sales, supply chain, finance and human resources. Doing so allows executives to examine and rate R&D's integration with the rest of the company. Also, benchmarking an assessment against the performance of top innovators can give a clear picture of R&D effectiveness (see Figure 1).
When R&D organizations in chemical companies are struggling to deliver on their promise, they are often suffering from one of three common failure modes.
Strong team running in too many directions. A lack of clarity about strategic direction or the source of profits can diffuse focus. Some companies spread their R&D investment too thinly across too many products, end markets and customers, hoping for a home run. These organizations frequently attract top researchers, but the lack of direction undermines R&D returns.
One specialty chemical company that was spreading its efforts across more than 40 end markets found that 70% of revenue and more than 95% of earnings came from just three markets. Its customer loyalty scores were higher than competitors in these areas, but it was spending less than half of its R&D resources there. By refocusing 80% of its R&D against those three areas, the company increased market share in its most profitable areas and was described by one analyst as having an R&D engine that is "the envy of the industry."
Narrowing the focus typically requires a few discrete actions.
Fascinated by cool engineering problems rather than customer needs. Challenging problems may be more interesting to work on than delivering features that customers will buy. Sometimes R&D hasn't invested enough time understanding customer needs and their product roadmap, or is unable to translate that into requirements. Bringing the customer's voice into the process takes several forms.
The operating model hinders execution. R&D's operating model should serve as a blueprint for the organization and management of resources. However, poor decision rights, weak stage-gate discipline and failure to define the right ways of working can make the operating model an obstacle to progress. Leading companies assess their operating models to ensure these imperatives.
Chemicals R&D doesn’t have to be a black box. Chemical companies that invest time assessing and transforming R&D reap significant benefits, including:
Improving R&D requires time, commitment from senior leaders and persistence to see it through to full potential. But it's a journey that every chemical company should be considering.
The fundamentals of Agile are straightforward: To capture an opportunity, form a small, cross-functional, empowered and self-managing team to focus on it. The methodology originated in the software industry, where it has improved the productivity of tens of thousands of software development projects by as much as 39%. Other industries have adopted the methodology, too, but it's been slow to catch on in chemicals.
An Agile team's initiative owner, typically drawn from a business function, uses techniques such as design thinking to build a catalog of promising ideas or features and to continuously (and ruthlessly) prioritize the list based on potential value to customers and the company. The team breaks top-priority tasks into small modules, decides how to work on them and then starts building working versions in short cycles known as sprints.
Among the most important success factors for applying Agile methods to R&D in the chemical industry:
Kayvan Ardalan is a partner with the Performance Improvement practice and leads Research and Product Development globally. He is based in Los Angeles. Whit Keuer and Bram Vanassche are partners in Bain’s Chemicals practice. Whit is based in the Dallas office, and Bram is based in the Brussels office.